Compare Amgen, Inc. (AMGN) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Lufax Holding Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Amgen, Inc. is far larger — about 81.4× Lufax Holding Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| AMGN | LU | |
|---|---|---|
Market Cap | $196.12B | $2.41B |
Sector | Health | Technology |
52-Week High | $388.16 | $4.40 |
52-Week Low | $271.18 | $1.23 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LU trades at $1.34, down 1.47% today, with a neutral technical signal and bearish moving averages. The company reported 2025 revenue of $23.1B but a net loss of $2.1B, with negative profit margins. Analyst consensus is 62% buy, but recent news highlights multiple class-action lawsuits filed against the company, creating significant legal overhangs. Cash flow trends show negative net cash flow of $709M in 2025, driven by heavy investing outflows.
The outlook is mixed: low valuation ratios (P/S 0.34, P/B 0.1) suggest potential upside if profitability improves, but persistent losses, legal risks, and negative cash flow pose substantial downside risks. Investors should weigh cheap valuation against execution challenges and litigation uncertainties in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
